Kymera Therapeutics (NASDAQ:KYMR) Trading Down 1.9% After Insider Selling

Kymera Therapeutics, Inc. (NASDAQ:KYMRGet Free Report) traded down 1.9% during trading on Monday following insider selling activity. The stock traded as low as $36.22 and last traded at $36.49. 178,419 shares changed hands during trading, a decline of 80% from the average session volume of 883,645 shares. The stock had previously closed at $37.21.

Specifically, insider Ellen Chiniara sold 3,295 shares of Kymera Therapeutics stock in a transaction on Thursday, January 4th. The stock was sold at an average price of $22.58, for a total value of $74,401.10. Following the completion of the sale, the insider now directly owns 34,205 shares of the company’s stock, valued at $772,348.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In related news, insider Jared Gollob sold 46,137 shares of Kymera Therapeutics stock in a transaction on Friday, February 9th. The stock was sold at an average price of $35.50, for a total value of $1,637,863.50. Following the completion of the transaction, the insider now directly owns 74,709 shares in the company, valued at $2,652,169.50. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Ellen Chiniara sold 3,295 shares of Kymera Therapeutics stock in a transaction on Thursday, January 4th. The shares were sold at an average price of $22.58, for a total value of $74,401.10. Following the completion of the transaction, the insider now owns 34,205 shares of the company’s stock, valued at $772,348.90. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 59,432 shares of company stock valued at $2,012,765. 16.67% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of research firms recently issued reports on KYMR. Wells Fargo & Company lowered Kymera Therapeutics from an “overweight” rating to an “equal weight” rating and set a $26.00 target price for the company. in a report on Tuesday, December 19th. HC Wainwright decreased their price target on Kymera Therapeutics from $85.00 to $30.00 and set a “buy” rating for the company in a report on Friday, November 3rd. Piper Sandler decreased their price target on Kymera Therapeutics from $58.00 to $38.00 and set an “overweight” rating for the company in a report on Friday, November 3rd. Morgan Stanley decreased their price target on Kymera Therapeutics from $37.00 to $24.00 and set an “equal weight” rating for the company in a report on Monday, November 13th. Finally, JPMorgan Chase & Co. raised Kymera Therapeutics from a “neutral” rating to an “overweight” rating in a report on Thursday, January 4th. Five research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $35.88.

Check Out Our Latest Report on Kymera Therapeutics

Kymera Therapeutics Stock Performance

The company has a 50-day simple moving average of $27.99 and a 200-day simple moving average of $21.06. The company has a market cap of $2.02 billion, a price-to-earnings ratio of -12.69 and a beta of 2.23.

Hedge Funds Weigh In On Kymera Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in KYMR. Amundi acquired a new position in Kymera Therapeutics during the 4th quarter worth approximately $49,000. Point72 Hong Kong Ltd purchased a new stake in shares of Kymera Therapeutics during the 1st quarter worth approximately $53,000. Advisors Asset Management Inc. purchased a new stake in shares of Kymera Therapeutics during the 4th quarter worth approximately $58,000. Royal Bank of Canada boosted its stake in shares of Kymera Therapeutics by 30.0% during the 2nd quarter. Royal Bank of Canada now owns 2,773 shares of the company’s stock worth $64,000 after acquiring an additional 640 shares in the last quarter. Finally, Tower Research Capital LLC TRC boosted its stake in shares of Kymera Therapeutics by 65.4% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,899 shares of the company’s stock worth $67,000 after acquiring an additional 1,146 shares in the last quarter.

About Kymera Therapeutics

(Get Free Report)

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.

Featured Stories

Receive News & Ratings for Kymera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kymera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.